Navigation Links
InspireMD Reports Financial Results for Quarter Ended September 30, 2013
Date:11/11/2013

eptember 30, 2013 Financial ResultsRevenue for the quarter ended September 30, 2013 was $1.6 million, an increase of 205% compared to $0.5 million for the same period in 2012.  The increase year over year reflects the positive impact of recent steps taken to stabilize the global distribution strategy and the early success of targeted selling activities in Brazil as well as select European countries.

Gross profit for the quarter ended September 30, 2013 totaled $0.8 million, an increase of 187% compared to $0.3 million for same period in 2012. The increase in gross profit is attributable to an increase in revenue of approximately $1.1 million, as described above, partially offset by an increase in cost of revenues of approximately $0.5 million. Gross margin for the three months ended September 30, 2013 was 51.7%, a decrease from 54.8% in the three months ended September 30, 2012. If the non-recurring effects of the consolidation of our manufacturing facilities in the three months ended September 30, 2013 are removed, gross margin for the three months ended September 30, 2013 would have been 63.1%.

Total operating expenses for the quarter ended September 30, 2013 were $4.7 million, an increase of 31.7% compared to $3.6 million for the same period in 2012. The increase was primarily due to an increase in startup costs associated with initiating the MASTER II trial, as well as increased sales and marketing expenses, as the Company begins to build the appropriate sales infrastructure for future growth.

The loss from operations for the quarter ended September 30, 2013 was $3.9 million, an increase of 18.4% compared to a loss of $3.3 million for the same period in 2012.

Total financial expenses for the quarter ended September 30, 2013 were $0.1 million, a decrease of 98.6% compared to $4.2 million in the same period in 2012. The decrease in financial expenses resulted primarily from the absence of any non-cash revaluations of our warrants
'/>"/>

SOURCE InspireMD
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. InspireMD Announces First Quarter 2012 Financial Results
2. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
3. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
4. InspireMD to Present at Harvard Investors Group on June 27 in New York
5. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
6. InspireMD Reports Results For Period Ending Sept. 30, 2012
7. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
8. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
9. InspireMD Reports Results for Period Ended Dec. 31, 2012
10. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
11. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... Mass., May 28, 2015  Shareholder rights law ... whether certain officers and directors of Eleven Biotherapeutics, ... Eleven Biotherapeutics is a clinical-stage biopharmaceutical company that ... therapeutics to treat eye diseases, primarily in ... View this press release on the law ...
(Date:5/28/2015)... 28, 2015   Eli Lilly and Company (NYSE: ... host a webcast on June 11 to discuss data from ... rheumatoid arthritis. Data from these two trials, RA-BEACON and RA-BUILD, will ... the EULAR Congress 2015 in Rome, Italy ... to11:00 a.m. Eastern Daylight Time. The live audio webcast can ...
(Date:5/28/2015)... ROCKLAND, Mass. , May 28, 2015 /PRNewswire/ ... a leading company for innovative and top-quality high-tech ... today announced a global collaboration agreement with the ... dedicated to advancing fertility science and helping couples ... Germany , a global market ...
Breaking Medicine Technology:Robbins Arroyo LLP Is Investigating the Officers and Directors of Eleven Biotherapeutics, Inc. (EBIO) on Behalf of Shareholders 2Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data 2Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase III Data 3Merck KGaA, Darmstadt, Germany, as Pioneer in Assisted Reproductive Treatments, Takes Leading Role in Fertility Technologies, Announces a Global Collaboration Agreement with Genea Biomedx 2Merck KGaA, Darmstadt, Germany, as Pioneer in Assisted Reproductive Treatments, Takes Leading Role in Fertility Technologies, Announces a Global Collaboration Agreement with Genea Biomedx 3Merck KGaA, Darmstadt, Germany, as Pioneer in Assisted Reproductive Treatments, Takes Leading Role in Fertility Technologies, Announces a Global Collaboration Agreement with Genea Biomedx 4
... SuccessEHS, a nationally recognized, streamlined practice management and ... recently named by the Arkansas Regional Extension Center (REC) ... health care initiatives. Regional Extension ... endowed by the Office of the National Coordinator for ...
... 17, 2011 ORTHOCON, Inc., a developer of implantable products ... to bone, today announced the U.S. launch of its first ... The HEMA SORB Absorbable Bone Hemostat ... absorbable putty that is designed to rapidly stop bleeding when ...
Cached Medicine Technology:Arkansas REC Selects SuccessEHS as Preferred Vendor 2Arkansas REC Selects SuccessEHS as Preferred Vendor 3ORTHOCON® Announces U.S. Market Launch of HEMASORB® 2
(Date:5/28/2015)... The Boys & Girls Club of Atlantic City ... Blue Shield of New Jersey (Horizon BCBSNJ) and through the ... receive much more support as play begins for the 2015 ... & Girls Club member and volunteer with the organization as ... accepted the Horizon Blue Cross Blue Shield of New Jersey ...
(Date:5/28/2015)... Scotch Plains, NJ (PRWEB) May 28, 2015 ... Dr. Farhad Rafizadeh, specializes in delivering world-class results. ... of Plastic Surgery and a background in art, Dr. ... look. His unique approach to Plastic Surgery involves ... addition, his practice delivers a superior level of comfort ...
(Date:5/28/2015)... 28, 2015 Ross A. Clevens, MD, ... has hired Teresa Beard as the new marketing director ... Beard will oversee all marketing and promotional events for ... leading teams and developing compelling marketing strategies to achieve ... Specialists, Beard served as guest communication manager at the ...
(Date:5/28/2015)... The Paw Project, an international ... intended to educate the Oregon public about the harmful ... of Market Street and Park Avenue in Salem, Oregon's ... De-clawing Cats, Raise Your Hand,” depicts a human hand ... a graphic and anatomically-correct representation of the declaw surgery ...
(Date:5/28/2015)... 2015 Altima Technologies, Inc., the ... for documenting and diagramming data center assets and ... following product lines: , Manufacturer / Device ... Products N-Series TeraFrame Cabinet, Middle Atlantic Products RSH ... Systems ForeRunner, Marantz America MM Series, Extron Electronics ...
Breaking Medicine News(10 mins):Health News:Golf Pro Natalie Gulbis to Chip in with Horizon Blue Cross Blue Shield of New Jersey to Support Boys & Girls Club of Atlantic City 2Health News:Golf Pro Natalie Gulbis to Chip in with Horizon Blue Cross Blue Shield of New Jersey to Support Boys & Girls Club of Atlantic City 3Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 2Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 3Health News:Clevens Face and Body Specialists Welcomes Teresa Beard as Marketing Director 2Health News:Declawing is Cruel, Education is the Key - Says the Paw Project 2Health News:Declawing is Cruel, Education is the Key - Says the Paw Project 3Health News:NetZoom™ Visio® Stencil Library Updates for EMC, Cisco, and Chatsworth Products 2
... BC, Oct. 15 /PRNewswire/ - Neuromed,Pharmaceuticals, a biopharmaceutical ... today it has successfully reached an,agreement with the ... Protocol Assessment (SPA) process for the planned pivotal ... the treatment of,chronic pain. A SPA is a ...
... Patients with Kidney Impairments - - ... of Patients -, CAMBRIDGE, Mass., Oct. 15 ... announced that the U.S. Food and,Drug Administration (FDA) ... patients with impaired kidney function, including those,requiring dialysis. ...
... LAVAL, QC, Oct. 15 /PRNewswire-FirstCall/ - Labopharm Inc. ... initiated the U.S. Food and Drug,Administration (FDA),s Formal ... Company,s once-daily formulation of,tramadol. Labopharm received a second ... of tramadol in May of this year. The ...
... It has supernatural effects on some diseases, but the ... reported in the November 7 issue of the World ... a Chinese medicinal compound, delisheng, for the therapy of ... was led by Dr. Ke-Jun Nan from The First ...
... over past decade , , MONDAY, Oct. 15 (HealthDay News) -- ... United States, offering what an expert called a "glimmer of ... report, cancer death rates fell by 2.1 percent each year ... annual decline recorded between 1993 and 2003. , "That,s a ...
... Philadelphia, PA, October 15, 2007 Using a ... cancer, epidemiologists and clinical researchers from Memorial Sloan-Kettering ... screening colonoscopy which clears pre-cancerous polyps from the ... Zauber, Ph.D., Sidney J. Winawer, M.D., MACG and ...
Cached Medicine News:Health News:Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077 2Health News:Neuromed Concludes a Special Protocol Assessment (SPA) with FDA for a Pivotal Phase 3 Study on NMED-1077 3Health News:FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma 2Health News:FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma 3Health News:FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma 4Health News:FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma 5Health News:FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma 6Health News:Labopharm appeals FDA's decision on once-daily tramadol 2Health News:A Chinese medicine compound has satisfactory anti-cancer effects on hepatocellular carcinoma 2Health News:U.S. Cancer Death Rate Continues to Fall 2Health News:U.S. Cancer Death Rate Continues to Fall 3Health News:First colonoscopy with removal of polyps linked to reduction in colon cancer death 2Health News:First colonoscopy with removal of polyps linked to reduction in colon cancer death 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: